Arcus Biosciences Stock Price, Forecast & Analysis (NYSE:RCUS)

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences Inc (NYSE:RCUS) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02. The company earned $1.75 million during the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative return on equity of 36.93% and a negative net margin of 1,180.37%. View Arcus Biosciences' Earnings History.

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

4 Wall Street analysts have issued 1-year target prices for Arcus Biosciences' shares. Their forecasts range from $15.00 to $22.00. On average, they expect Arcus Biosciences' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 149.0% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

News stories about RCUS stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arcus Biosciences earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Arcus Biosciences.

Arcus Biosciences saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,010,000 shares, an increase of 11.0% from the September 30th total of 1,810,000 shares. Based on an average trading volume of 251,100 shares, the days-to-cover ratio is currently 8.0 days. Approximately 7.3% of the shares of the stock are sold short. View Arcus Biosciences' Current Options Chain.

Some companies that are related to Arcus Biosciences include Epizyme (EPZM), Zymeworks (ZYME), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Innoviva (INVA), BELLUS Health (BLUSF), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), AnaptysBio (ANAB), Y-mAbs Therapeutics (YMAB), ZEALAND PHARMA/S (ZEAL), Endo International (ENDP) and Stoke Therapeutics (STOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Fate Therapeutics (FATE), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX), Cidara Therapeutics (CDTX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Parallel Advisors LLC (0.19%), Rhumbline Advisers (0.11%), Russell Investments Group Ltd. (0.05%), California Public Employees Retirement System (0.04%), Bailard Inc. (0.03%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc.. View Insider Buying and Selling for Arcus Biosciences.

RCUS stock was bought by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers and Meeder Asset Management Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $7.63.

Arcus Biosciences has a market capitalization of $349.90 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

The official website for Arcus Biosciences is http://www.arcusbio.com/.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]